Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Generic Drugs
Pharmaceutical company receives U.S. FDA approval for generic antifungal agent
February 20th, 2005
Teva Pharmaceutical Industries Ltd. (TEVA) announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company's ANDA for fluconazole injection, 2 mg/mL in 200 mg and 400 mg bags. A launch date has not yet been finalized. Fluconazole is the generic equivalent of Pfizer's antifungal agent Diflucan. Total annual sales of this configuration of fluconazole injection, including brand and generic sales, are approximately $167 million. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is a generic pharmaceutical company that develops, manufactures and markets generic and innovative human...
Source: Medical Letter on the CDC & FDA (2005-02-20)
|
